Oncology Biosimilars Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global oncology biosimilars market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the oncology biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Oncology Biosimilars market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider oncology biosimilars market, and compares it with other markets.
Scope
Markets Covered: 1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF); 2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Others; 3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Biocoin; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the oncology biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Oncology Biosimilars market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider oncology biosimilars market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
- The oncology biosimilars market section of the report gives context. It compares the oncology biosimilars market with other segments of the oncology biosimilars market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, oncology biosimilars indicators comparison.
Scope
Markets Covered: 1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF); 2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Others; 3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Biocoin; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Executive Summary2. Oncology Biosimilars Market Characteristics26. Key Mergers And Acquisitions In The Oncology Biosimilars Market27. Oncology Biosimilars Market Trends And Strategies28. Oncology Biosimilars Market Future Outlook and Potential Analysis
3. Oncology Biosimilars Market Size And Growth
4. Oncology Biosimilars Market Segmentation
5. Oncology Biosimilars Market Regional And Country Analysis
6. Asia-Pacific Oncology Biosimilars Market
7. China Oncology Biosimilars Market
8. India Oncology Biosimilars Market
9. Japan Oncology Biosimilars Market
10. Australia Oncology Biosimilars Market
11. Indonesia Oncology Biosimilars Market
12. South Korea Oncology Biosimilars Market
13. Western Europe Oncology Biosimilars Market
14. UK Oncology Biosimilars Market
15. Germany Oncology Biosimilars Market
16. France Oncology Biosimilars Market
17. Eastern Europe Oncology Biosimilars Market
18. Russia Oncology Biosimilars Market
19. North America Oncology Biosimilars Market
20. USA Oncology Biosimilars Market
21. South America Oncology Biosimilars Market
22. Brazil Oncology Biosimilars Market
23. Middle East Oncology Biosimilars Market
24. Africa Oncology Biosimilars Market
25. Oncology Biosimilars Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
The oncology biosimilars market consists of sales of medicine and drug related products for cancer treatment. Biosimilars are pharmaceuticals which are manufactured using cell lines and are exclusive to the manufacturer. The manufacturing of these cell line processes is a complex and time-consuming process.The global oncology biosimilars market was worth $2990.34 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 33.17% and reach $9404.54 million by 2023.
The oncology biosimilars market covered in this report is segmented by drug type into monoclonal antibody, immunomodulators, hematopoietic agents, granulocyte colony-stimulating factor (G-CSF). It is also segmented by cancer type into breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, others and by distribution type into hospital pharmacy, retail pharmacy and online pharmacy.
The expiration of patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms which induces the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offers the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.
The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of detailed awareness on the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported in 2018 by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.
The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting growth potential of rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in the fiscal year 2017, Aurobindo Pharma spent $80 million to support the research for the biosimilars including oncology biosimilars. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up R&D facility to boost biosimilar development.
Major players in the market are Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH and BIOCAD.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biocoin
- Celltrion Inc.
- Dr. Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Ltd.
- STADA Arzneimittel AG
- Pfizer Inc.
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- BIOCAD
- Amgen
- Hospira
- F Hoffmann-La Roche
- Baxter
- Sanofi
- Mylan
- F Hoffmann-La Roche
Methodology
LOADING...
